Biogen (BIIB) Receives Buy Rating with $255 Target Following Leqembi Approval

Biogen (BIIB) Stock Jumps on Analyst Upgrade Before Key Alzheimer’s Data Release

Truist upgrades Biogen (BIIB) stock to Buy with $235 target ahead of Alzheimer's drug data. Shares rise 1.3% premarket on positive analyst o

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

This could be a key move for future growth.

Biogena Group Invest Aktie: 25 Millionen für Direct-Market-Plus

Biogena Group Invest bereitet den Sprung in den Direct Market Plus vor. Der Salzburger Mikronährstoff-Spezialist setzt dabei auf eine deutli

Q32 Bio stock soared after its alopecia drug cleared a key clinical bar

The biotech's Phase 2a study of bempikibart showed a 35.3% mean reduction in hair loss scores, with the company planning a registration-dire

Biogen's Q2 2026 Earnings: What to Expect

Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen

The "Affordable Growth" strategy targets stocks with strong growth and reasonable valuations. Neurocrine Biosciences (NBIX) fits perfectly,